4/19
11:01 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/5
08:38 am
imux
ATOS, SMR and EIGR are among pre market gainers [Seeking Alpha]
Medium
Report
ATOS, SMR and EIGR are among pre market gainers [Seeking Alpha]
4/5
08:03 am
imux
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $10.00 price target on the stock.
4/4
08:10 am
imux
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors [Yahoo! Finance]
Low
Report
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors [Yahoo! Finance]
4/4
06:34 am
imux
Immunic to Host MS R&D Day and Participate in Investor Conferences in April [Yahoo! Finance]
Low
Report
Immunic to Host MS R&D Day and Participate in Investor Conferences in April [Yahoo! Finance]
4/4
06:30 am
imux
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Low
Report
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
3/29
11:08 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Neutral
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/21
12:33 pm
imux
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month [Yahoo! Finance]
Low
Report
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month [Yahoo! Finance]
3/21
11:46 am
imux
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy [Yahoo! Finance]
Low
Report
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy [Yahoo! Finance]
3/20
06:38 am
imux
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States [Yahoo! Finance]
Low
Report
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States [Yahoo! Finance]
3/20
06:30 am
imux
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Low
Report
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
3/11
11:00 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/11
11:00 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/8
06:59 am
imux
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024 [Yahoo! Finance]
Low
Report
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024 [Yahoo! Finance]
3/7
06:36 am
imux
Immunic to Participate in Investor and Scientific Conferences in March [Yahoo! Finance]
Neutral
Report
Immunic to Participate in Investor and Scientific Conferences in March [Yahoo! Finance]
3/7
06:30 am
imux
Immunic to Participate in Investor and Scientific Conferences in March
Low
Report
Immunic to Participate in Investor and Scientific Conferences in March
2/29
06:45 am
imux
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 [Yahoo! Finance]
Medium
Report
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 [Yahoo! Finance]
2/29
06:30 am
imux
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Medium
Report
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
2/23
09:19 pm
imux
Immunic Inc (IMUX) Reports Year-End 2023 Financial Results [Yahoo! Finance]
Medium
Report
Immunic Inc (IMUX) Reports Year-End 2023 Financial Results [Yahoo! Finance]
2/23
11:23 am
imux
Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/22
11:08 am
imux
Immunic reports successful 2023 and prepares for key 2025 milestones [Yahoo! Finance]
Medium
Report
Immunic reports successful 2023 and prepares for key 2025 milestones [Yahoo! Finance]
2/22
06:41 am
imux
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/22
06:30 am
imux
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
2/15
06:46 am
imux
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update [Yahoo! Finance]
Medium
Report
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update [Yahoo! Finance]
2/15
06:30 am
imux
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Low
Report
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update